Ligands of Immunopharmacology

Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.In VitroRosmanol exhibits the strongest inhibition on cell viability

Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.In VitroRosmanol exhibits the strongest inhibition on cell viability

Salicylic acid-d 6 is a deuterium labeled Salicylic acid. Salicylic acid inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation.Form:SolidIC50&amp Target:COX-2 Autophagy Mitophagy Apoptosis

Salicylic acid-d 6 is a deuterium labeled Salicylic acid. Salicylic acid inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation.Form:SolidIC50&amp Target:COX-2 Autophagy Mitophagy Apoptosis

Salicylic acid-d 6 is a deuterium labeled Salicylic acid. Salicylic acid inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation.Form:SolidIC50&amp Target:COX-2 Autophagy Mitophagy Apoptosis

SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K i value of 10 µM SK1-I shows no activity at SPHK1 PKCα, PKCδ , PKA , AKT1 , ERK1 , EGFR , CDK2 , IKKβ or CamK2β. SK1-I enhances autophagy and has

SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K i value of 10 µM SK1-I shows no activity at SPHK1 PKCα, PKCδ , PKA , AKT1 , ERK1 , EGFR , CDK2 , IKKβ or CamK2β. SK1-I enhances autophagy and has

SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K i value of 10 µM SK1-I shows no activity at SPHK1 PKCα, PKCδ , PKA , AKT1 , ERK1 , EGFR , CDK2 , IKKβ or CamK2β. SK1-I enhances autophagy and has

SK1-IN-1 is a potent sphingosine kinase 1 ( SPHK1 ) inhibitor with an IC 50 of 58 nM.In VivoSK1-IN-1 demonstrates significant improvement in the intrinsic clearance, particularly against human liver microsomes. SK1-IN-1 is selected for rat PK

SK1-IN-1 is a potent sphingosine kinase 1 ( SPHK1 ) inhibitor with an IC 50 of 58 nM.In VivoSK1-IN-1 demonstrates significant improvement in the intrinsic clearance, particularly against human liver microsomes. SK1-IN-1 is selected for rat PK

SK1-IN-1 is a potent sphingosine kinase 1 ( SPHK1 ) inhibitor with an IC 50 of 58 nM.In VivoSK1-IN-1 demonstrates significant improvement in the intrinsic clearance, particularly against human liver microsomes. SK1-IN-1 is selected for rat PK

SK1-IN-1 is a potent sphingosine kinase 1 ( SPHK1 ) inhibitor with an IC 50 of 58 nM.In VivoSK1-IN-1 demonstrates significant improvement in the intrinsic clearance, particularly against human liver microsomes. SK1-IN-1 is selected for rat PK